Frequently Asked Questions

Per FDA labeling, GLP-1 medications for weight management are generally considered for adults with a BMI of 30+, or 27+ with a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea. Only an independent licensed provider can review your medical history and determine whether a medication is appropriate for you. This is general education, not medical advice.

GLP3 Weight Loss is an independent educational resource. We are not a clinic, pharmacy, or telehealth provider. We do not prescribe, dispense, see patients, or sell treatment. We provide education and can help you find an independent, third-party licensed provider who handles any evaluation, prescription, dosing, and monitoring.

We provide education on GLP-1 receptor agonists semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro/Zepbound), both FDA-approved, and on the investigational triple agonist retatrutide (GLP-3), which is not FDA-approved and remains in clinical trials. Any prescribing decision is made only by an independent licensed provider.

These figures describe what researchers observed in published trials, not results we offer, promise, or provide. Trials reported roughly 15% average body-weight reduction with semaglutide and 21% with tirzepatide; a Phase 2 trial of the investigational retatrutide reported about 24%. Individual outcomes vary, and only a licensed provider can advise on what to expect.

GLP-1 receptor agonists are prescription medications that mimic the incretin hormone GLP-1 to reduce appetite, slow gastric emptying, and improve blood sugar regulation. "GLP-3" is an informal term for retatrutide, an investigational triple-agonist compound that targets GLP-1, GIP, and glucagon receptors. Retatrutide is investigational and not FDA-approved. This is general education, not medical advice.

"GLP-3" is an informal term for retatrutide, an investigational triple agonist targeting three receptors instead of one or two. The added glucagon receptor activation is associated in trials with increased energy expenditure and hepatic fat oxidation. A Phase 2 trial reported about 24% average body-weight reduction. Retatrutide is investigational and not FDA-approved; these are trial observations, not results we offer.

The most commonly reported side effects are mild gastrointestinal symptoms — nausea, vomiting, diarrhea, and constipation — which typically subside within 2-4 weeks. A licensed provider who prescribes the medication uses a gradual dose-escalation approach and monitors for side effects. GLP3 Weight Loss does not provide medical monitoring.

Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management. Retatrutide (GLP-3) is investigational and not FDA-approved — it remains in clinical trials. We clearly label investigational compounds on our site. GLP3 Weight Loss does not prescribe or dispense any medication.

GLP3 Weight Loss does not sell treatment plans or set medication prices. Pricing for GLP-1 / GLP-3 therapy is determined by the independent licensed provider and pharmacy you choose, and varies. We can refer you to independent providers; any medication, evaluation, and fees are handled entirely by them.

Coverage varies by insurance plan and individual circumstances. An independent provider's office can verify your coverage and discuss options, including any out-of-network or HSA/FSA reimbursement. GLP3 Weight Loss does not bill insurance, set medication pricing, or sell treatment.

If an independent licensed provider prescribes an approved medication, the prescription is filled and shipped by a licensed pharmacy. GLP3 Weight Loss does not prescribe, dispense, or ship medication, and is not involved in your care.

Refills and follow-up care are arranged entirely between you and the independent licensed provider you choose. GLP3 Weight Loss does not manage refills, run a patient portal, or provide follow-up care.

Research indicates weight regain is possible after discontinuation. A licensed provider can discuss maintenance strategies, nutrition, and behavioral support that extend beyond medication alone. This is general education, not medical advice, and GLP3 Weight Loss does not direct your care.

In trials, significant weight loss was reported without mandatory exercise protocols, though physical activity supports overall health and helps preserve lean muscle. Any personalized guidance on activity should come from a licensed provider. This is general education, not medical advice.

If you are currently on a GLP-1 medication, an independent licensed provider can evaluate your regimen and decide how to proceed. GLP3 Weight Loss does not manage prescriptions, hold your records, or arrange transfers; we provide education and referrals only.

GLP3 Weight Loss is not a HIPAA covered entity. We do not hold protected health information, run a patient portal, or manage prescriptions. We do not sell or share site-visitor information with unrelated third parties. You can review our full privacy policy for details.